Aortic stenosis and atrial fibrillation after TAVR or SAVR

Severe aortic stenosis and atrial fibrillation (AF) frequently converge in older adults, creating a clinical problem that extends beyond valve gradients and procedural survival. A narrowed aortic valve increases left ventricular pressure, promotes diastolic dysfunction and raises left atrial pressure. Over time, atrial enlargement and fibrosis can establish a substrate for AF, while AF itself may worsen symptoms, reduce cardiac output and increase embolic risk.

The choice between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) can influence the rhythm course after treatment. TAVR generally causes less surgical stress and tends to produce less early postoperative AF, whereas SAVR may offer different long-term considerations, including coronary access, valve durability and the need for concomitant surgical procedures. Arrhythmia outcomes should therefore be assessed alongside age, frailty, anatomy, anticoagulation requirements and the expertise of the treating heart team.

Why aortic stenosis creates an arrhythmia substrate

Pressure overload from a stenotic aortic valve leads to concentric left ventricular hypertrophy. As the ventricle becomes stiffer, filling pressures rise and transmit pressure backwards to the left atrium. Persistent stretch can cause atrial dilation, electrical remodelling and patchy fibrosis, all of which make atrial tachyarrhythmias more likely.

AF may be paroxysmal, persistent or clinically silent. Some people present with palpitations, reduced exercise tolerance or irregular pulse, while others are diagnosed after a stroke or during routine monitoring. Once AF is established, rapid ventricular rates can aggravate breathlessness and heart failure symptoms that might otherwise be attributed solely to aortic stenosis.

Valve replacement can reduce the haemodynamic burden, but it does not instantly reverse atrial remodelling. Patients with longstanding AF, marked left atrial enlargement or significant mitral regurgitation may remain at risk after a technically successful procedure. This distinction is important when counselling patients about the expected rhythm benefits of valve intervention.

How TAVR and SAVR affect early postoperative AF

New-onset AF is a well-recognised complication after cardiac surgery. With SAVR, atrial manipulation, cardiopulmonary bypass, inflammation, catecholamine release, fluid shifts and postoperative pain can create a potent short-term trigger. Rates vary according to the population and monitoring strategy, but clinically significant postoperative AF is generally more common after SAVR than after TAVR.

TAVR avoids sternotomy and cardiopulmonary bypass, so early AF may be less frequent and hospital recovery may be faster. This advantage is particularly relevant for older people with frailty, chronic lung disease or limited physiological reserve. It does not mean that TAVR eliminates arrhythmia risk: pre-existing AF remains common, and new atrial arrhythmias can still occur in the setting of haemodynamic stress, infection, anaemia or renal dysfunction.

Evidence from randomised trials and registries should be interpreted carefully. TAVR and SAVR populations may differ in age, surgical risk, anatomical complexity and follow-up duration. Studies also vary in whether they count brief telemetry episodes, clinically treated AF or rhythm documented after discharge. These differences can make the apparent gap between procedures look larger or smaller than the underlying biological effect.

The significance of pre-existing atrial fibrillation

AF present before valve replacement is a marker of advanced atrial and cardiovascular disease. It is associated with higher risks of stroke, heart failure admission, bleeding and mortality after both TAVR and SAVR. Valve replacement may improve symptoms and ventricular loading conditions, but it does not remove the indication for stroke prevention when thromboembolic risk remains elevated.

Anticoagulation decisions should be based on an integrated assessment rather than the procedural label alone. In Australia, clinicians commonly use the CHA₂DS₂-VASc framework alongside bleeding risk, renal function, falls, frailty and patient preferences. Direct oral anticoagulants are widely used when appropriate, while warfarin remains important for selected patients, including those with mechanical valves or specific clinical indications.

The timing of anticoagulant interruption and resumption requires coordination among the structural heart team, electrophysiology service, anaesthesia team and primary care clinician. TAVR usually involves antithrombotic planning around vascular access and prosthetic valve thrombosis, while SAVR may involve additional considerations related to surgical bleeding and any concomitant bypass or valve procedures.

Conduction disease and pacemaker risk after TAVR

The main rhythm concern after TAVR is often not AF but conduction system injury. The prosthetic valve frame sits close to the atrioventricular node and the His-Purkinje system. Pressure on these structures can produce new left bundle branch block, high-grade atrioventricular block or delayed conduction deterioration.

Permanent pacemaker rates vary considerably with valve design, implantation depth, baseline electrocardiogram and patient anatomy. A pacemaker can prevent bradycardia and allow safe discharge, yet implantation carries procedural risks and creates a lifelong device follow-up requirement. New conduction abnormalities may also complicate interpretation of symptoms after discharge.

SAVR can cause conduction problems as well, particularly when annular calcification is extensive or surgery involves the aortic root. Its pacemaker risk is often lower than that reported with some TAVR platforms, although the comparison depends on device generation and patient selection. A Heart Team should discuss conduction risk explicitly rather than presenting TAVR as the universally simpler rhythm option.

Stroke prevention and rhythm monitoring after valve replacement

The combination of a prosthetic valve, postoperative inflammation and AF can make stroke prevention complex. A short episode of AF detected in hospital may resolve, while recurrent or sustained AF after discharge can indicate a longer-term arrhythmia burden. Decisions about continuing anticoagulation should account for documented recurrence, stroke risk and bleeding hazards rather than relying on whether sinus rhythm was restored before discharge.

Monitoring may include inpatient telemetry, a 12-lead ECG, ambulatory patches, event recorders or an implantable loop recorder in selected cases. Wearable devices and consumer smartwatches can identify an irregular pulse, but an ECG-quality recording and clinical assessment are needed before diagnosing AF and prescribing treatment. The role of extended monitoring is especially relevant for patients with unexplained neurological events; current discussions of device-detected episodes illustrate why episode duration and patient risk profile matter.

After TAVR or SAVR, monitoring should be directed by symptoms, baseline rhythm, conduction changes and the consequences of a missed arrhythmia. Syncope, unexplained fatigue, recurrent breathlessness, palpitations or a persistently slow pulse warrant prompt review. Follow-up should also confirm valve function, ventricular recovery and medication tolerance.

What the Australian setting adds to the decision

Australia’s valve service is organised across large metropolitan centres, regional hospitals and referral networks. A patient in western New South Wales, regional Queensland or rural Western Australia may need to travel to Sydney, Brisbane or Perth for valve imaging and intervention. TAVR can shorten inpatient recovery, which may reduce time away from home, but post-procedure ECG surveillance and access to urgent review still need to be planned before discharge.

The public and private systems also differ in waiting times, referral pathways and access to specialist follow-up. Local multidisciplinary heart teams generally weigh age, surgical risk, life expectancy, valve anatomy, coronary access and patient preference. For an older person in Melbourne or Adelaide, the rhythm implications may influence the choice between procedures; for a younger patient, durability, future coronary intervention and lifetime management may carry greater weight.

Australia’s geography makes remote monitoring and clear handover particularly valuable. A patient returning to the bush after TAVR may need a documented plan for ECG checks, wound or access-site review, anticoagulation management and escalation if conduction symptoms develop. General practitioners, cardiologists, cardiac rehabilitation teams and Aboriginal and Torres Strait Islander health services can all contribute to continuity of care when specialist services are several hours away.

Building a patient-specific rhythm strategy

The most useful comparison between TAVR and SAVR is not simply the average rate of postoperative AF. Clinicians should assess the patient’s baseline rhythm, left atrial size, ventricular function, conduction intervals, coronary anatomy, frailty, kidney function and likely need for anticoagulation. A patient with paroxysmal AF and high stroke risk may require a different plan from someone with no AF but significant baseline conduction disease.

For SAVR, preventive strategies may include beta-blocker continuation when safe, correction of electrolyte abnormalities, careful fluid management and treatment of triggers such as infection or hypoxia. If AF occurs, rate control, rhythm control and anticoagulation should be considered according to haemodynamic stability and the expected duration of the episode. Cardioversion may be appropriate in selected patients, but thromboembolic risk must be addressed.

For TAVR, the pathway should include baseline and post-procedure ECGs, observation for delayed heart block and a clear approach to new bundle branch block. Medication choices should avoid unnecessary antithrombotic exposure, particularly in older adults with anaemia, renal impairment or a history of gastrointestinal bleeding. Contemporary evidence and practical electrophysiology education are available through the Journal of Arrhythmia, including research relevant to structural heart interventions and device-based monitoring.

The strongest care plans are shared decisions. Patients should understand that TAVR may reduce early surgical stress and postoperative AF, while SAVR may be preferable when anatomy, durability or the need for combined surgery points in that direction. Neither procedure guarantees freedom from AF, and both require structured surveillance for stroke, bleeding, bradycardia and recurrent symptoms.

Clinicians, researchers and trainees can use current electrophysiology evidence to refine assessment of AF burden, conduction complications and antithrombotic care after valve replacement. Reviewing contemporary studies and discussing individual cases through multidisciplinary heart teams can help translate TAVR-versus-SAVR evidence into safer rhythm care for patients across Australia.